
Global R&D Pipeline
My Favorite
Hot Targets:
c-Kit
Back
Total number of drugs
184
Phase II and later clinical stages
20.1%
Involving companies
229
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bezuclastinib | Bezuclastinib | Small molecule drug | Neoplasms Digestive System Disorders Skin and Musculoskeletal Diseases Other Diseases Immune System Diseases Hemic and Lymphatic Diseases | Stem cell growth factor receptor inhibitors | Plexxikon, Inc. | Cogent Biosciences, Inc. | NDA/BLA | United States | Bezuclastinib | detail > | |||||||||||
| Nilotinib Hydrochloride | Nilotinib Hydrochloride | Small molecule drug | Neoplasms Hemic and Lymphatic Diseases Nervous System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases Other Diseases Immune System Diseases Endocrinology and Metabolic Disease | Colony stimulating factor 1 receptor antagonists Discoidin domain receptor 1 antagonists Stem cell growth factor receptor inhibitors | Novartis Pharma AG | Novartis Pharmaceuticals Corp.Accord Healthcare SLNovartis AGNovartis Europharm Ltd.Azurity Pharmaceuticals, Inc.Totalclarity, Inc.Xspray Pharma ABNovartis Pharma Schweiz AGNovartis Pharmaceuticals (HK) Ltd.Georgetown UniversityNovartis Pharma KKNovartis Pharmaceuticals Australia Pty Ltd. | Approved | Approved | United States China European Union Japan United Kingdom Australia Switzerland Iceland Liechtenstein Norway | 2007-07-24 | 2009-07-14 | United States | Nilotinib Hydrochloride | detail > | |||||||
| Dashatinib | Dashatinib | Small molecule drug | Neoplasms Immune System Diseases Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases Nervous System Diseases Cardiovascular Diseases Congenital Disorders Digestive System Disorders Other Diseases | Ephrin type-A receptor 2 antagonists Tyrosine-protein kinase FYN inhibitors Tyrosine-protein kinase LCK inhibitors Platelet-derived growth factor receptor beta inhibitors Tyrosine-protein kinase SRC inhibitors Yes tyrosine protein kinase inhibitors Stem cell growth factor receptor inhibitors | Bristol Myers Squibb Co. | Accord Healthcare SLBristol Myers Squibb Co.Bristol-Myers Squibb Pharma EEIGGeorgetown UniversityXspray Pharma ABThe Naval Medical University of PLAHanda Pharmaceuticals, Inc.Wayne State University FoundationGSK PlcAstex Pharmaceuticals, Inc.UCL School of PharmacyProDigest BVUniversity of Pittsburgh School of MedicineYale School of Medicine | Approved | Approved | United States China European Union Japan Australia Iceland Liechtenstein Norway | 2006-06-28 | 2011-09-07 | United States | Dashatinib | detail > | |||||||
| Sunitinib Malate | Sunitinib Malate | Small molecule drug | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Skin and Musculoskeletal Diseases Urogenital Diseases Other Diseases Eye Diseases | Colony stimulating factor 1 receptor antagonists Tyrosine-protein kinase receptor FLT3 inhibitors Platelet-derived growth factor receptor alpha inhibitors Platelet-derived growth factor receptor beta inhibitors Tyrosine-protein kinase receptor RET inhibitors Vascular endothelial growth factor receptor 1 antagonists Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitors | Pfizer Inc. | Pfizer Japan, Inc.C.P. Pharmaceuticals International CVPfizer Australia Pty Ltd.Pfizer Ltd.Accord Healthcare SLPfizer Inc.Pfizer Italia Srl | Approved | Approved | United States China European Union Japan United Kingdom Australia Iceland Liechtenstein Norway | 2006-01-26 | 2007-10-30 | United States | Sunitinib Malate | detail > | |||||||
| Sorafenib Tosylate | Sorafenib Tosylate | Small molecule drug | Neoplasms Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Other Diseases Respiratory Diseases Congenital Disorders | Serine/threonine-protein kinase B-raf inhibitors C-Raf kinase inhibitors Tyrosine-protein kinase receptor FLT3 inhibitors Platelet-derived growth factor receptor beta inhibitors Tyrosine-protein kinase receptor RET inhibitors Vascular endothelial growth factor receptor 1 antagonists Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitors | Onyx Pharmaceuticals, Inc. | Genentech, Inc.Merck Sharp & Dohme Corp.Fudan UniversityBayer Australia Ltd.Bayer AGBayer Healthcare LLCAccord Healthcare SLBayer PlcDisruptive Pharma AB (Sweden)Bayer Yakuhin Ltd.Bayer HealthCare Pharmaceuticals, Inc.Hutchison MediPharma Ltd.Bayer HealthCare AGBayer Schering Pharma AG | Approved | Approved | United States China European Union Japan United Kingdom Australia Iceland Liechtenstein Norway | 2005-12-01 | 2006-09-12 | United States | Sorafenib Tosylate | detail > | |||||||
| Imatinib mesylate | Imatinib mesylate | Small molecule drug | Neoplasms Immune System Diseases Digestive System Disorders Hemic and Lymphatic Diseases Skin and Musculoskeletal Diseases Other Diseases Respiratory Diseases Congenital Disorders | Bcr-Abl tyrosine kinase inhibitors Platelet-derived growth factor receptor alpha inhibitors Stem cell growth factor receptor inhibitors | Novartis Pharma AG | Hangzhou Chance Pharmaceuticals Co., Ltd.The Children's Oncology Group Foundation, Inc.Novartis Europharm Ltd.Novartis Pharmaceuticals Corp.Teva Pharmaceuticals Europe BVNovartis Pharmaceuticals Australia Pty Ltd.Accord Healthcare SLNovartis Pharma KKUniversity of California San DiegoNational Cancer InstituteShorla Pharma Ltd.Novartis Pharma Schweiz AGUniversity of Wisconsin-MadisonTenax Therapeutics, Inc. | Approved | Approved | United States China European Union Japan Australia Iceland Liechtenstein Norway | 2001-05-10 | 2002-04-01 | United States | Imatinib mesylate | detail > | |||||||
| Barzolvolimab | Barzolvolimab | Monoclonal antibody | Immune System Diseases Skin and Musculoskeletal Diseases Congenital Disorders | Stem cell growth factor receptor inhibitors | Yale University | Celldex Therapeutics, Inc. | Phase 3 | Barzolvolimab | detail > | ||||||||||||
| Famitinib Malate | Famitinib Malate | Small molecule drug | Neoplasms Urogenital Diseases Respiratory Diseases Skin and Musculoskeletal Diseases Digestive System Disorders Other Diseases | AXL receptor tyrosine kinase inhibitors Fibroblast growth factor receptors antagonists Tyrosine-protein kinase Mer inhibitors Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitors | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Fudan UniversityJiangsu Hengrui Pharmaceuticals Co., Ltd.Hengrui (USA) Ltd. | Approved | Approved | China | 2025-05-27 | 2025-05-27 | China | Famitinib Malate | detail > | |||||||
| Cediranib | Cediranib | Small molecule drug | Neoplasms Nervous System Diseases Digestive System Disorders Endocrinology and Metabolic Disease Urogenital Diseases Other Diseases Respiratory Diseases Skin and Musculoskeletal Diseases | Platelet-derived growth factor receptor beta inhibitors Vascular endothelial growth factor receptor 1 antagonists Vascular endothelial growth factor receptor 2 antagonists Vascular endothelial growth factor receptor 3 antagonists Stem cell growth factor receptor inhibitors | AstraZeneca PLC | AstraZeneca PLCNational Cancer InstituteThe University of Texas MD Anderson Cancer Center | Phase 3 | Phase 3 | United States | Cediranib | detail > | ||||||||||
| Olverembatinib | Olverembatinib | Small molecule drug | Neoplasms Hemic and Lymphatic Diseases Immune System Diseases Digestive System Disorders Skin and Musculoskeletal Diseases Other Diseases Urogenital Diseases | BCR-ABL T315I mutation inhibitors Stem cell growth factor receptor inhibitors | Guangzhou Shunjian Biomedical Technology Co. Ltd. | Ascentage Pharma Group International Co., Ltd.Ascentage Pharma Group, Inc.Innovent Biologics, Inc.Guangzhou Shunjian Biomedical Technology Co. Ltd. | Approved | Approved | China Macao | 2021-11-24 | 2021-11-24 | Breakthrough Therapy | Olverembatinib | detail > |
Total 184 data
1
2
3
4
5
6
...
18
19


